Literature DB >> 16928243

Intralesional therapy of metastatic spreading melanoma with beta-interferon.

Harriet Rapprich1, Manfred Hagedorn.   

Abstract

A 74-year-old female patient developed multiple local metastases after excision of a nodular melanoma of the left cheek. There was no regression after treatment with dacarbazine (DTIC) and radiotherapy. After treatment with intralesional interferon-beta, the metastases regressed completely. The dosage was 5 million IU interferon-beta (Fiblaferon) three times weekly with courses of two and four weeks, separated by a month. Except for local swelling and inflammation, no side effects occurred. Five years after completing therapy, the patient is still tumor-free.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16928243     DOI: 10.1111/j.1610-0387.2006.06054.x

Source DB:  PubMed          Journal:  J Dtsch Dermatol Ges        ISSN: 1610-0379            Impact factor:   5.584


  3 in total

Review 1.  [Therapy of cutaneous metastases of malignant melanoma].

Authors:  P Rehberger; S Eppinger; A Stein; J Schmitt
Journal:  Hautarzt       Date:  2006-12       Impact factor: 0.751

2.  Immunomodulatory effect of peritumorally administered interferon-beta on melanoma through tumor-associated macrophages.

Authors:  Aya Kakizaki; Taku Fujimura; Sadanori Furudate; Yumi Kambayashi; Takeshi Yamauchi; Hideo Yagita; Setsuya Aiba
Journal:  Oncoimmunology       Date:  2015-05-26       Impact factor: 8.110

3.  Phase I study of nivolumab combined with IFN-β for patients with advanced melanoma.

Authors:  Taku Fujimura; Takanori Hidaka; Yumi Kambayashi; Sadanori Furudate; Aya Kakizaki; Hisayuki Tono; Akira Tsukada; Takahiro Haga; Akira Hashimoto; Ryo Morimoto; Takuhiro Yamaguchi; Tadao Takano; Setsuya Aiba
Journal:  Oncotarget       Date:  2017-04-13
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.